Awarded Grants

Click on any project title for a more detailed description of the project. For more information about any of these awards (e.g., PI contact information or associated publications), please use the corresponding project number to search for information at the NIH Reporter website. Consistent with NIH policy, abstracts are not available for projects receiving their first award within the past year, so descriptions provided below are from the NCI program director.

New FY2016 awards will be posted as they are issued.

Grant Year	Grant Award Type	Project Number	Grant PI Name	Title
2017	R21	CA231000-01A1	KENNEDY, DANIEL ROBERT (contact); ZWICKER, JEFFREY	Response to PQ12 - Using thiol isomerase inhibitors to diminish cancer induced thrombosis
2017	R01	CA231267-01	FEHRENBACHER, JILL C (contact); KELLEY, MARK R	(PQ12) Enhancement of DNA repair in neurons via a targeted APE1 small molecule modifier to decrease and reverse chemotherapy-induced peripheral neuropathy (CIPN)
2017	R01	CA227493-01	MARPLES, BRIAN (contact); FORNONI, ALESSIA	(PQ 12) Targeting SMPDL3b to Prevent Radiation-Induced Nephrotoxicity
2017	R01	CA219637-01A1	DAMAJ, M IMAD (contact); GEWIRTZ, DAVID A	(PQ12) Peroxisome proliferator-activated receptor alpha agonists as potential treatment for chemotherapy-induced peripheral neuropathy
2017	R01	CA219829-01A1	ZHANG, ZHENG GANG	Exosomes and platinum-induced peripheral neuropathy
2017	R01	CA242158-01	JANG, MI-HYEON	PQ#12; Targeting Nampt-mediated NAD+ metabolism in chemobrain
2017	R01	CA227517-01A1	TANIGUCHI, CULLEN MITSUO	Translating Intestinal Radioprotection by EGLN Inhibition to Improve Clinical Outcomes in Unresectable Pancreatic Cancer
2017	R01	CA220002-01A1	BURRIDGE, PAUL W (contact); STRANGER, BARBARA E	Genomic Prediction of Doxorubicin-Induced Cardiotoxicity
2017	R21	CA231131-01A1	CARSON, JAMES A	(PQ 12) The Regulation of Physical Function and Skeletal Muscle Metabolic Signaling After Cessation of 5-Fluorouracil Treatment
2017	R01	CA227064-01	KAVELAARS, ANNEMIEKE (contact); HEIJNEN, COBI J	PQ12 Targeting HDAC6 for Chemotherapy-Induced Neuropathy and Chemobrain
2017	R01	CA238946-01	LUSTBERG, MARYAM B (contact); HU, SHUIYING	Prevention of paclitaxel-induced peripheral neuropathy with nilotinib
2017	R01	CA231219-01	ARONSON, WILLIAM J (contact); COHEN, PINCHAS	Role of GPR120 and Macrophages in Dietary Omega-3 Fatty Acid Inhibition of Prostate Cancer
2017	R01	CA227479-01	SIMONE, NICOLE L	(11) Diet Modification to Augment Radiation for Breast Cancer Brain Metastases
2017	R01	CA231239-01A1	ACHARYYA, SWARNALI	Modulating dietary zinc to prevent cachexia and improve survival in cancer
2017	R21	CA238953-01	VISWANATHAN, SARASWATHI (contact); RACHAGANI, SATYANARAYANA	Altered Histidine Metabolism in Pancreatic Cancer: A Novel Metabolic Target to Enhance Gemcitabine Efficacy
2017	R21	CA242270-01	KAISER, PETER	Methionine Dependency of Cancer
2017	R21	CA231255-01	ROSENBERG, DANIEL WILLIAM	(PQ11) Dietary strategies to enhance FOLFOX cancer therapies
2017	R01	CA227230-01A1	CHEN, SHIUAN (contact); LAU, CLAYTON; TWARDOWSKI, PRZEMYSLAW WIKTOR	(PQ11) Immune modulatory effects of white button mushroom in prostate cancer - A translational research
2017	R21	CA227528-01	WEICHSELBAUM, RALPH R	(PQ10) Understanding How Commensal Microbiota Affect the Anti-tumor Action of Radiotherapy
2017	R01	CA219896-01A1	WARGO, JENNIFER A	(PQ10) Enhancing responses to immune checkpoint blockade in melanoma via modulation of the microbiome
2017	R01	CA219871-01A1	FACCIABENE, ANDREA (contact); KOUMENIS, CONSTANTINOS	(PQ10) The impact of the gut microbiome on the anti-tumor effects of radiotherapy
2017	R21	CA231273-01A1	WEICHSELBAUM, RALPH R	Microbiota and the anti-tumor action of anti-CD47 immunomodulation.
2017	R21	CA227232-01	TURNBAUGH, PETER JAMES (contact); ATREYA, CHLOE E	(PQ10) Harnessing the human gut microbiome to predict chemotherapy outcomes
2017	R01	CA231303-01A1	KOH, ANDREW Y (contact); HOMSI, JADE ; PASARE, CHANDRASHEKHAR	Role of Gut Microbiota in Modulating Immune Checkpoint Inhibitory Therapy for Cancer
2017	R01	CA242305-01	JAMES, LINDSEY INGERMAN	Discovery of first-in-class nsd2 degraders for cancer therapy
2017	R01	CA238570-01	CREWS, CRAIG M	Developing Tumor-specific PROTACs
2017	R01	CA230854-01	JIN, JIAN (contact); PARSONS, RAMON E	(PQ9) Developing EZH2 Degraders for Treating Triple-Negative Breast Cancer
2017	R01	CA242003-01	ZHOU, DAOHONG (contact); TREVINO, JOSE G; ZHENG, GUANGRONG	Use of BCL-xL Proteolysis targeting chimeras to treat pancreatic cancer
2017	R01	CA231295-01	OSMAN, IMAN (contact); WEBER, JEFFREY S	(PQ8) Predicting immune-related toxicity in the adjuvant melanoma setting with checkpoint inhibition
2017	R01	CA227466-01	ZIV, ELAD	(8) Genetics of Immune Related Adverse Events and Response to Immunotherapy
2017	R21	CA231277-01A1	MOR, ADAM	(PQ8) Predictive biomarkers for the onset of immune-related adverse events associated with PD-1 blockade
2017	R01	CA231291-01	WELLSTEIN, ANTON (contact); ATKINS, MICHAEL BENJAMIN	(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors
2017	R01	CA227481-01A1	BALKO, JUSTIN M (contact); JOHNSON, DOUGLAS B	(PQ8) Patient- and tumor-specific biomarkers and mechanisms that predict irAEs resulting from checkpoint inhibition
2017	R21	CA231280-01A1	FANTL, WENDY JANE (contact); LEPPERT, JOHN THOMAS	(PQ8) Biomarker identification by mass cytometry in peripheral blood of patients with renal cell carcinoma undergoing immune checkpoint therapy
2017	R01	CA231226-01A1	BUCKNER, JANE HOYT (contact); CHOW, LAURA ; LINSLEY, PETER S; WAMBRE, ERIC	Defining the features of T cell response to tumor and self-antigens as predictors of response to checkpoint therapy
2017	R01	CA227505-01	KIRCHHOFF, TOMAS (contact); WEBER, JEFFREY S	(8) Genomic determinants of the T-cell regulome in immune checkpoint blockade
2017	R01	CA238471-01	DHODAPKAR, KAVITA (contact); SANZ, IGNACIO E	B cells in autoimmunity following checkpoint blockade therapy
2017	R01	CA238998-01	WEIDHAAS, JOANNE B	Germ-line miRNA binding site variants as biomarkers of toxicity and response to checkpoint inhibition
2017	R01	CA227473-01	HEROLD, KEVAN C (contact); KLUGER, HARRIET M	(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors
2017	R21	CA231252-01A1	ASTSATUROV, IGOR (contact); CUKIERMAN, EDNA	Oncogenic Synapses: cell-cell contacts enabling trogocytic-based metabolic interactions between pancreatic cancer and fibroblastic stromal cells
2017	R01	CA242226-01	ROGERS, GREGORY CHARLES (contact); CRESS, ANNE E	Centrosome instability as a mechanism to promote localized prostate cancer
2017	R21	CA231269-01A1	LUSK, CHARLES PATRICK (contact); KING, MEGAN C	Leveraging cancer-specific defects in nuclear integrity to inform novel synthetic lethal strategies
2017	R01	CA231300-01A1	BIVONA, TREVER G (contact); HUANG, BO	(PQ7) Defining a new mode of RAS signaling in cancer from cytoplasmic protein granules
2017	R21	CA227381-01	GADDAMEEDHI, SHOBHAN	Chronotherapy as a Strategy to Attenuate Toxicity Associated with Cisplatin and Radiation Treatment for Triple-Negative Breast Cancer
2017	R01	CA230848-01	FU, LONING NONE (contact); MOORE, DAVID D	(PQ6)Nuclear receptor mechanisms in circadian disruption induced hepatocarcinogenesis
2017	R21	CA227379-01	HONG, CHRISTIAN I	(PQ6) Roles of circadian rhythms in tumor development
2017	R01	CA231321-01A1	BURCH, JAMES	Role of Circadian Factors in Inflammation and Colorectal Adenoma Risk
2017	R21	CA227375-01	REPASKY, ELIZABETH A (contact); ANTOCH, MARINA	(PQ6): Is Adrenergic Stress-induced Immune Suppression at the Crossroads of Circadian Rhythm Disruption and Cancer?
2017	R01	CA231122-01A1	HELLER, H CRAIG	(#6) A novel animal model for determining the role of circadian timing in breast cancer development
2017	R01	CA238988-01	FU, LONING NONE (contact); MOORE, DAVID D	Sympathetic circadian dysfunction in obesity-related hepatocarcinogenesis

Search form

You are here

Awarded Grants

Pages